Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quintiles Enters Malaysia Clinical Trial Alliance For First Prime Site In Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Quintiles has entered an alliance with the University Malaya Medical Centre, creating its first clinical trial Prime Site in Asia, which is focused on accelerating drug development

You may also be interested in...

Malaysia Health Ministry Is Both "Promoter and Regulator" Of Industry – Minister Liow Tiong Lai

The Ministry of Health lessens its reliance on counterpart agencies as it rolls out new pharmacoeconomic guidelines.

Malaysia Gears Up To Launch Second VC Fund To Support Life Sciences – Biopharma Asia Conference

Malaysia readies to launch venture capital fund worth $100 million in the second quarter to support biopharma industry.

Seoul National University Hospital Partners With Quintiles On Clinical Trials

SEOUL - Seoul National University Hospital, which is at the forefront of the government's drive to make South Korea a hub for global clinical trials, has signed a strategic alliance agreement to take part in Quintiles' Prime Site program

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts